secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021281
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix Q1 revenue $9.1M (+38% YoY); core lung diagnostics up 86% to $8.6M
---------------------------------------------------------------------------

- Total revenue $9.1M, +38% YoY; core lung diagnostic revenue $8.6M, +86% YoY.
- Net loss $18.7M ($0.24 per share); operating expenses $22.3M up 25% YoY.
- Gross margin improved to 65% from 51% due to shift from lower-margin COVID-19 tests.
- COVID-19 testing revenue down 99% YoY; company discontinues commercial COVID-19 testing.
- Reaffirmed 2023 total revenue guidance $52M-$55M; cash $25.3M as of March 31.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017023021281/0000950170-23-021281-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017023021281/bdsx-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021281

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer